Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 34, Issue 1, 2007, Pages 35-55

  Kshirsagar, Smita A ^a   Blaschke, Terrence F ^a   Sheiner, Lewis B ^c,d   Krygowski, M ^e   Acosta, Edward P ^f   Verotta, Davide ^b,d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UCSF Dept Epidemiol Biostatist   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Indinavir; Nephrotoxicity; Non compliance; Prior

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIVIRUS AGENT; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; AUTOANALYSIS; CLINICAL TRIAL; COMPUTER PROGRAM; DATA ANALYSIS; DATA BASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; NEPHROLITHIASIS; NEPHROTOXICITY; PRIORITY JOURNAL; RELIABILITY;

ADULT; DATA INTERPRETATION, STATISTICAL; DATABASES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; KIDNEY DISEASES; MALE; MODELS, BIOLOGICAL; PATIENT COMPLIANCE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SOFTWARE;

EID: 33846274204     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9032-2     Document Type: Article

References (48)

1. J. Lu, J. M. Gries, D. Verotta, and L. B. Sheiner. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J. Pharmacokinet. Pharmacodyn. 28:343-362 (2001).
2. L. B. Sheiner and J. L. Steimer. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40:67-95 (2000).
3. C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, and J. H. Rodman. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Clin. Pharmacol. 34:111-119 (1994).
4. Guidance for Industry on Population Pharmacokinetics (1999). Available at: http://www.fda.gov/cder/guidance/1852fnl.pdf
5. L. Aarons, L. P. Balant, F. Mentre, P. L. Morselli, M. Rowland, J. L. Steimer, and S. Vozeh. Practical experience and issues in designing and performing population pharmacokinetic/ pharmacodynamic studies. Eur. J. Clin. Pharmacol. 49:251-254 (1996).
6. B. Vrijens and E. Goetghebeur. The impact of compliance in pharmacokinetic studies. Stat. Methods Med. Res. 8:247-262 (1999).
7. J. Urquhart. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin. Pharmacokinet. 27:202-215 (1994).
8. L. S. Morris and R. M. Schulz. Patient compliance - an overview. J. Clin. Pharm. Ther. 17:283-295 (1992).
9. P. Girard, T. F. Blaschke, H. Kastrissios, and L. B. Sheiner. A Markov mixed effect regression model for drug compliance. Stat. Med. 17:2313-2333 (1998).
10. L. A. Kenna and L. B. Sheiner. Estimating treatment effect in the presence of noncompliance measured with error: precision and robustness of data analysis methods. Stat. Med. 23:3561-3580 (2004).
11. D. Soy, S. L. Beal, and L. B. Sheiner. Population one-compartment pharmacokinetic analysis with missing dosage data. Clin. Pharmacol. Ther. 76:441-451 (2004).
12. S. Mu and T. M. Ludden. Estimation of population pharmacokinetic parameters in the presence of non-compliance. J. Pharmacokinet. Pharmacodyn. 30:53-81 (2003).
13. T. R. Ten Have, M. Joffe, and M. Cary. Causal logistic models for non-compliance under randomized treatment with univariate binary response. Stat. Med. 22:1255-1283 (2003).
14. T. Sato. A method for the analysis of repeated binary outcomes in randomized clinical trials with non-compliance. Stat. Med. 20:2761-2774 (2001).
15. P. A. Korhonen, N. M. Laird, and J. Palmgren. Correcting for non-compliance in randomized trials: an application to the ATBC Study. Stat. Med. 18:2879-2897 (1999).
16. E. N. Jonsson, J. R. Wade, G. Almqvist, and M. O. Karlsson. Discrimination between rival dosing histories. Pharm. Res. 14:984-991 (1997).
17. R. M. Gulick, A. Meibohm, D. Havlir, J. J. Eron, A. Mosley, J. A. Chodakewitz, R. Isaacs, C. Gonzalez, D. McMahon, D. D. Richman, M. Robertson, and J. W. Mellors. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. Aids 17:2345-2349 (2003).
18. A. J. Olyaei, A. M. deMattos, and W. M. Bennett. Renal toxicity of protease inhibitors. Curr. Opin. Nephrol. Hypertens. 9:473-476 (2000).
19. D. L. Gentle, M. L. Stoller, T. W. Jarrett, J. F. Ward, K. S. Geib, and A. F. Wood. Protease inhibitor-induced urolithiasis. Urology 50:508-511 (1997).
20. R. G. Bruce, L. C. Munch, A. D. Hoven, R. S. Jerauld, R. Greenburg, W. H. Porter, and P. W. Rutter. Urolithiasis associated with the protease inhibitor indinavir. Urology 50:513-518 (1997).
21. J. P. Dieleman, I. C. Gyssens, M. E. van der Ende, S. de Marie, and D. M. Burger. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Aids 13:473-478 (1999).
22. J. P. Dieleman, M. C. Sturkenboom, M. Jambroes, I. C. Gyssens, G. J. Weverling, J. H. ten Veen, G. Schrey, P. Reiss, and B. H. Stricker. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch. Intern. Med. 162:1493-1501 (2002).
23. J. P. Dieleman, A. M. van Rossum, B. C. Stricker, M. C. Sturkenboom, R. de Groot, D. Telgt, W. L. Blok, D. M. Burger, B. G. Blijenberg, R. Zietse, and I. C. Gyssens. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J. Acquir. Immune. Defic. Syndr. 32:135-142 (2003).
24. E. Martinez, M. Leguizamon, J. Mallolas, J. M. Miro, and J. M. Gatell. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin. Infect. Dis. 29:422-425 (1999).
25. E. Saltel, J. B. Angel, N. G. Futter, W. G. Walsh, K. O'Rourke, and J. E. Mahoney. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J. Urol. 164:1895-1897 (2000).
26. C. Solas, S. Basso, I. Poizot-Martin, I. Ravaux, H. Gallais, J. A. Gastaut, A. Durand, and B. Lacarelle. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J. Acquir. Immune. Defic. Syndr. 29:374-377 (2002).
27. S. E. Sutherland, M. D. Reigle, A. D. Seftel, and M. I. Resnick. Protease inhibitors and urolithiasis. J. Urol. 158:31-33 (1997).
28. L. D. Trainor, J. P. Steinberg, G. W. Austin, and H. M. Solomon. Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. Arch. Pathol. Lab. Med. 122:256-259 (1998).
29. R. F. Gagnon, S. N. Tecimer, A. K. Watters, and C. M. Tsoukas. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am. J. Kidney Dis. 36:507-515 (2000).
30. J. B. Kopp, J. Falloon, A. Filie, A. Abati, C. King, G. L. Hortin, J. M. Mican, E. Vaughan, and K. D. Miller. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin. Infect. Dis. 34:1122-1128 (2002).
31. J. B. Kopp, K. D. Miller, J. A. Mican, I. M. Feuerstein, E. Vaughan, C. Baker, L. K. Pannell, and J. Falloon. Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. 127:119-125 (1997).
32. J. R. Wade, A. W. Kelman, C. A. Howie, and B. Whiting. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J. Pharmacokinet. Biopharm. 21:209-222 (1993).
33. P. O. Gisleskog, M. O. Karlsson, and S. L. Beal. Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Pharmacodyn. 29:473-505 (2002).
34. S. L. Beal and L. B. Sheiner (eds.). NONMEM Users Guide, NONMEM Project Group, University of California at San Francisco, San Francisco, 1992.
35. R. M. Gulick, L. M. Smeaton, R. T. D'Aquila, J. J. Eron, J. S. Currier, J. G. Gerber, E. Acosta, J. P. Sommadossi, R. Tung, S. Snyder, D. R. Kuritzkes, and R. L. Murphy. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J. Infect. Dis. 183:715-721 (2001).
36. R. DiCenzo, A. Forrest, M. A. Fischl, A. Collier, J. Feinberg, H. Ribaudo, R. DiFrancecso, and G. D. Morse. Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 48:918-923 (2004).
37. M. A. Fischl, H. J. Ribaudo, A. C. Collier, A. Erice, M. Giuliano, M. Dehlinger, J. J. Eron, Jr., M. S. Saag, S. M. Hammer, S. Vella, G. D. Morse, J. E. Feinberg, L. M. Denter, and S. H. Eshleman. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J. Infect. Dis. 188:625-634 (2003).
38. M. Pfister, L. Labbe, J. F. Lu, S. M. Hammer, J. Mellors, K. K. Bennett, S. Rosenkranz, and L. B. Sheiner. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin. Pharmacol. Ther. 72:133-141 (2002).
39. M. Pfister, L. Labbe, S. M. Hammer, J. Mellors, K. K. Bennett, S. Rosenkranz, and L. B. Sheiner. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. 47:130-137 (2003).
40. E. P. Acosta, H. Wu, S. M. Hammer, S. Yu, D. R. Kuritzkes, A. Walawander, J. J. Eron, C. J. Fichtenbaum, C. Pettinelli, D. Neath, E. Ferguson, A. J. Saah, and J. G. Gerber. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 37:1358-1366 (2004).
41. X. J. Zhou, D. V. Havlir, D. D. Richman, E. P. Acosta, M. Hirsch, A. C. Collier, P. Tebas, and J. P. Sommadossi. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. Aids 14:2869-2876 (2000).
42. R. P. van Heeswijk, A. I. Veldkamp, R. M. Hoetelmans, J. W. Mulder, G. Schreij, A. Hsu, J. M. Lange, J. H. Beijnen, and P. L. Meenhorst. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. Aids 13:F95-99 (1999).
43. D. M. Burger, P. W. Hugen, R. E. Aarnoutse, J. P. Dieleman, J. M. Prins, T. van der Poll, J. H. ten Veen, J. W. Mulder, P. L. Meenhorst, W. L. Blok, J. T. van der Meer, P. Reiss, and J. M. Lange. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J. Acquir. Immune Defic. Syndr. 26:218-224 (2001).
44. T. N. Kakuda, L. M. Page, P. L. Anderson, K. Henry, T. W. Schacker, F. S. Rhame, E. P. Acosta, R. C. Brundage, and C. V. Fletcher. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob. Agents Chemother. 45:236-242 (2001).
45. E. P. Acosta, K. Henry, L. Baken, L. M. Page, and C. V. Fletcher. Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708-712 (1999).
46. C. Csajka, C. Marzolini, K. Fattinger, L. A. Decosterd, A. Telenti, J. Biollaz, and T. Buclin. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 48:3226-3232 (2004).
47. R. E. Aarnoutse, J. C. Wasmuth, G. Fatkenheuer, K. Schneider, K. Schmitz, T. M. de Boo, P. Reiss, Y. A. Hekster, D. M. Burger, and J. K. Rockstroh. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antivir. Ther. 8:309-314 (2003).
48. S. Sisson. Trans-dimensional Markov chains: a decade of progress and future perspectives. J. Am. Statis. Assoc. 100:1077-1089 (2005).